Pharma-Bio Serv Inc. reported its financial results for the quarter ending July 31, 2025. The company's gross profit increased by 6.6 percentage points compared to the same period last year, primarily due to improved margins in the Puerto Rico and United States consulting markets, as well as a high-margin project in the European market. The company experienced a projected revenue decline in its consulting markets in Puerto Rico, the US, and Brazil, amounting to approximately $0.8 million, $0.4 million, and $0.1 million, respectively. Despite these regional declines, the overall gross profit improved. Management stated that the company's future profitability and liquidity will depend on the effects of the local and global economy, including factors such as regional or global conflicts, price inflation, and pandemics, on their operations. There were no significant off-balance sheet arrangements or changes to critical accounting policies during the nine months ended July 31, 2025. Additionally, no new accounting standards were issued that would significantly impact the company's financial statements.